Jiyan Liu
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Research top 10%
Papers in
- Oncology 60
- Cancer Immunotherapy and Biomarkers 21
- Colorectal Cancer Treatments and Studies 19
- Pancreatic and Hepatic Oncology Research 6
-
- Gastric Cancer Management and Outcomes 11
- Renal cell carcinoma treatment 9
- Co-authors
- Yuwen Zhou (21 shared papers)Xuelei Ma (7 shared papers)Tingting Jiang (10 shared papers)Yajuan Zhu (8 shared papers)Zhenyu Ding (6 shared papers)Ji‐Cheng Li (10 shared papers)Liansha Tang (11 shared papers)Xiuyun Yang (6 shared papers)
- Journals
- Journal of Clinical Oncology (20 papers)Frontiers in Oncology (7 papers)Anti-Cancer Drugs (4 papers)Cancer Medicine (4 papers)Frontiers in Immunology (4 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Jiyan Liu
154 papers receiving 3.0k citations
Jiyan Liu's Hit Papers
Peers
Comparison fields: 5 of 119
- Oncology 905
- Cancer Research 262
- Immunology 354
- Infectious Diseases 261
- Pulmonary and Respiratory Medicine 378
Countries citing papers authored by Jiyan Liu
This map shows the geographic impact of Jiyan Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiyan Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiyan Liu more than expected).
Fields of papers citing papers by Jiyan Liu
This network shows the impact of papers produced by Jiyan Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiyan Liu. The network helps show where Jiyan Liu may publish in the future.
Co-authors
The 25 scholars most cited alongside Jiyan Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 164 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Hit paper breakdown → | 2020 | 212 |
| 2 | 2011 | 145 | |
| 3 | 2007 | 122 | |
| 4 | 2013 | 119 | |
| 5 | 2021 | 88 | |
| 6 | 2019 | 84 | |
| 7 | 2021 | 83 | |
| 8 | 2019 | 81 | |
| 9 | 2013 | 78 | |
| 10 | 2020 | 75 | |
| 11 | 2011 | 73 | |
| 12 | 2013 | 69 | |
| 13 | 2019 | 68 | |
| 14 | 2017 | 66 | |
| 15 | 2010 | 63 | |
| 16 | 2014 | 62 | |
| 17 | 2022 | 51 | |
| 18 | 2014 | 50 | |
| 19 | 2008 | 42 | |
| 20 | 2013 | 40 |
About Jiyan Liu
Jiyan Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Cancer Research, having authored 164 papers that have together received 3.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (21 papers), Colorectal Cancer Treatments and Studies (19 papers), Bladder and Urothelial Cancer Treatments (14 papers), Gastric Cancer Management and Outcomes (11 papers), Renal cell carcinoma treatment (9 papers), Epigenetics and DNA Methylation (8 papers), Immunotherapy and Immune Responses (8 papers) and Pancreatic and Hepatic Oncology Research (6 papers). The work is most often cited by research in Oncology (905 citations), Cancer Research (262 citations), Immunology (354 citations), Infectious Diseases (261 citations) and Pulmonary and Respiratory Medicine (378 citations). Jiyan Liu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Yuwen Zhou, Xuelei Ma, Tingting Jiang, Yajuan Zhu, Zhenyu Ding, Ji‐Cheng Li, Liansha Tang, Xiuyun Yang, Liliang Wei and Ye Chen. Their work appears in journals such as Journal of Clinical Oncology, Frontiers in Oncology, Anti-Cancer Drugs, Cancer Medicine and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.